Quince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Update

Quince Therapeutics, Inc. (NASDAQ:QNCX) saw a significant drop in short interest in the month of January. As of January 30th, there was short interest totaling 1,875,868 shares, a drop of 45.7% from the January 15th total of 3,454,280 shares. Based on an average daily volume of 6,834,214 shares, the days-to-cover ratio is presently 0.3 days. Approximately 4.0% of the shares of the company are sold short. Approximately 4.0% of the shares of the company are sold short. Based on an average daily volume of 6,834,214 shares, the days-to-cover ratio is presently 0.3 days.

Institutional Investors Weigh In On Quince Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Bridgeway Capital Management LLC increased its holdings in Quince Therapeutics by 20.9% in the second quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock valued at $212,000 after purchasing an additional 22,200 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Quince Therapeutics in the 2nd quarter valued at about $37,000. Intellectus Partners LLC acquired a new stake in shares of Quince Therapeutics in the 4th quarter valued at approximately $179,000. GSA Capital Partners LLP boosted its stake in Quince Therapeutics by 158.0% during the 3rd quarter. GSA Capital Partners LLP now owns 87,235 shares of the company’s stock worth $142,000 after acquiring an additional 53,417 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Quince Therapeutics by 14.8% during the 4th quarter. Renaissance Technologies LLC now owns 538,100 shares of the company’s stock worth $1,803,000 after acquiring an additional 69,502 shares during the last quarter. 30.75% of the stock is owned by institutional investors and hedge funds.

Quince Therapeutics Trading Up 28.6%

Shares of NASDAQ QNCX opened at $0.29 on Friday. Quince Therapeutics has a 1 year low of $0.13 and a 1 year high of $4.55. The firm’s 50-day moving average is $2.70 and its 200-day moving average is $2.15. The firm has a market capitalization of $16.15 million, a PE ratio of -0.23 and a beta of 1.22.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.05). As a group, equities research analysts anticipate that Quince Therapeutics will post -1.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

QNCX has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Quince Therapeutics in a research note on Monday, December 29th. Citigroup cut shares of Quince Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, January 30th. Brookline Capital Acquisition lowered shares of Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 29th. Lucid Cap Mkts downgraded shares of Quince Therapeutics from a “strong-buy” rating to a “strong sell” rating in a report on Friday, January 30th. Finally, Citizens Jmp lowered shares of Quince Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, January 30th. Two analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Quince Therapeutics currently has an average rating of “Hold” and a consensus target price of $8.00.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.